par Carbonnaux, Mélodie;Souquet, Pierre-Jean;Meert, Anne-Pascale 
;Scherpereel, Arnaud;Peters, Matthew;Couraud, Sébastien
Référence The European respiratory journal, 47, 5, page (1502-1509)
Publication Publié, 2016-05
;Scherpereel, Arnaud;Peters, Matthew;Couraud, SébastienRéférence The European respiratory journal, 47, 5, page (1502-1509)
Publication Publié, 2016-05
Article révisé par les pairs
| Résumé : | Epidermal growth factor receptor gene (EGFR) mutation status has emerged as a crucial issue in lung cancer management. Availability and cost of tests and tyrosine kinase inhibitors (TKIs) may vary as a function of country development. We conducted a prospective specialist opinion survey to map EGFR test and EGFR-TKI availability and detect associations with the Human Development Index (HDI). A questionnaire was sent to specialists in thoracic oncology in all United Nations Member States. We obtained responses from 74 countries, comprising 78% of the worldwide population. Nonresponding countries had significantly lower HDI rank than responding countries. EGFR mutation analysis was routinely available in 57 countries (70% of the worldwide population). The cost of the test was |
